Results 81 to 90 of about 5,591 (212)

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Current and emerging “at-site” pain medications: a review

Journal of Pain Research, 2011
Praveen PN Rao, Tarek MohamedSchool of Pharmacy, Health Sciences Campus, University of Waterloo, Waterloo, ON, CanadaAbstract: The myriad pain pathophysiology has intrigued and challenged humanity for centuries.
Rao PPN, Mohamed T
doaj  

Cannabigerol reverses mechanical allodynia through α2A‐adrenergic modulation of thalamocortical signaling in chemotherapy‐induced neuropathy

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Chemotherapy‐induced peripheral neuropathy (CIPN) is a prevalent and treatment‐resistant side effect of platinum‐based chemotherapy, characterised by mechanical allodynia. Cannabigerol (CBG), a non‐psychoactive cannabinoid, has shown antinociceptive potential, but its site and mechanism of action remain unclear.
Quinn W. Wade, Nathan Morris, Diana E. Sepulveda, Alonso Cortez‐Resendiz, Christopher Brandl, Jennifer E. Lausch, Mariya Starostina, Nicholas M. Graziane   +7 more
wiley   +1 more source

Insights into cannabinoid receptor 2 (CB2) anterograde trafficking and pharmacological chaperoning

Cellular and Molecular Life Sciences
Cannabinoid Receptor 2 (CB2) is a promising therapeutic target for modulating inflammation. Canonical signalling responses to receptor ligands are critically dependent on cell surface receptor expression.
Caitlin R. M. Oyagawa, Braden Woodhouse, Karren C. Wood, Michelle Glass, Natasha L. Grimsey   +4 more
doaj   +1 more source

Covalent fluorescent probes for 2‐arachidonoylglycerol metabolic pathways

British Journal of Pharmacology, EarlyView.
Abstract Covalent fluorescent probes have emerged as versatile chemical tools to visualise active enzymes in complex biological systems. When tailored for specific applications, ranging from activity‐based protein profiling for drug development to high spatiotemporal resolution imaging of enzymatic activities, these probes provide unique insights into ...
Nick D. F. Puijmbroeck, Mario van der Stelt   +1 more
wiley   +1 more source

Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) and cannabigerol (CBG) alleviate hepatic steatosis in obese mice by shifting energy buffering towards phosphocreatine and enhancing lysosomal lipid degradation and trafficking. These effects are associated with increased creatine kinase activity and lysobisphosphatidic acid (LBPA) levels, highlighting a previously unrecognised ...
Radka Kočvarová, Shahar Azar, Bella Agranovich, Ifat Abramovich, Saveliy Kirillov, Alina Nemirovski, Saja Baraghithy, Inbar Plaschkes, Emmanuelle Merquiol, Alexander Rouvinski, Galia Blum, Liad Hinden, Joseph Tam   +12 more
wiley   +1 more source

2019 Academic Annual Meeting and the Frontier Seminar on “Glial Cell Function and Disease” (Nantong, China)

ASN Neuro, 2019
The contribution of glial activities to the functions, diseases, and repair of the central nervous system has received increasing attention in neuroscience studies.
Yu-Feng Wang, Yong-Jing Gao
doaj   +1 more source

Defining AV2‐1 as a novel pharmacological probe to target human and rodent TRPV2

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Transient receptor potential vanilloid 2 (TRPV2) is a non‐selective cation channel implicated in immune cell functions. However, progress in understanding TRPV2 has been limited by a lack of potent and selective pharmacological tools, particularly those targeting the human variant. We aimed to identify and characterise a
Andrea Leipe, Julia A. Rocereta, Ruth A. Pumroy, Andreas Leffler, Michael Schaefer, Vera Moiseenkova‐Bell, Kerstin Hill   +6 more
wiley   +1 more source

5‐HT2A receptor agonism by tert‐leucinamide and valinamide synthetic cannabinoids: In vitro and in vivo evidence

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose New synthetic cannabinoid receptor agonists (SCRAs) are associated with severe adverse effects, including unexpected psychiatric symptoms. These compounds are mainly active through their potent agonism on the cannabinoid receptors CB1 and CB2.
Giorgia Corli, Deborah Rudin, Dino Luethi, Matthias E. Liechti, Sabrine Bilel, Matteo Marti, Henrik Green, Manuela Carla Monti, Caitlyn Norman   +8 more
wiley   +1 more source

Cannabinoid Receptor 2 Signaling Does Not Modulate Atherogenesis in Mice

PLoS ONE, 2011
Strong evidence supports a protective role of the cannabinoid receptor 2 (CB(2)) in inflammation and atherosclerosis. However, direct proof of its involvement in lesion formation is lacking. Therefore, the present study aimed to characterize the role of the CB(2) receptor in Murine atherogenesis.Low density lipoprotein receptor-deficient (LDLR ...
Willecke, Florian, Zeschky, Katharina, Ortiz Rodriguez, Alexandra, Colberg, Christian, Auwärter, Volker, Kneisel, Stefan, Hutter, Melanie, Lozhkin, Andrey, Hoppe, Natalie, Wolf, Dennis, Zur Mühlen, Constantin von, Moser, Martin, Hilgendorf, Ingo, Bode, Christoph, Zirlik, Andreas   +14 more
openaire   +5 more sources